[{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1\/2a Study Arm Evaluating VB10.NEO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NORWAY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$715.0 million","upfrontCash":"$200.0 million","newsHeadline":"Vaccibody Enters into Worldwide License and Collaboration Agreement with Genentech to Develop Individualized Neoantigen Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$715.0 million","upfrontCash":"$200.0 million","newsHeadline":"Vaccibody Announces the Closing of the Worldwide License and Collaboration Agreement with Genentech","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$925.0 million","upfrontCash":"$30.0 million","newsHeadline":"Nykode Therapeutics (formerly Vaccibody*) Enters Into Multi-Target License and Collaboration Agreement with Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Therapeutics to Present at 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Therapeutics Announces Positive Interim Results From Its Phase 2 trial with VB10.16 in Combination With Immune Checkpoint Inhibitor Atezolizumab in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Therapeutics Announces Positive Results from the Phase 1\/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1\/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Therapeutics Presents Additional Efficacy Analysis In Phase 2 Study Of VB10.16 In Combination With Atezolizumab In Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA\u00ae (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Announces Expanded Clinical Development Plan For Its Lead Cancer Vaccine VB10.16 in HPV16-positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"GOG Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Therapeutics Announces Positive Final Results from Its Phase 2 Trial Of VB10.16 in Combination with PD-L1 Inhibitor Atezolizumab in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the next trial in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Vaccibody
The collaboration aims to cover evaluation of VB10.16, an off-the-shelf therapeutic cancer vaccine, in combination with Roche’s cancer immunotherapy atezolizumab in patients with advanced cervical cancer. Nykode will sponsor the trial, and Roche will provide atezolizumab.
VB10.16 is a potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate targeting antigens to antigen presenting cells. It is in development for the treatment of human papillomavirus type 16 (HPV16)-positive cancers.
Based on the positive interim data and in line with our potential registrational trial strategy, we look forward to starting the VB-C-04 trial in the U.S. The trial is aimed at providing a fast path to making VB10.16 available to patients.
VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. The drug candidate has reported interim data from VB-C-02, a Phase 2 trial in heavily pre-treated cervical cancer patients.
VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. Under the terms of the agreement, Merck will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.
Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive interim efficacy and safety results from its Phase 2 trial for the treatment of cervical cancer.
VB10.2210 is designed to induce T cell responses against epitopes from seven additional antigens that are highly conserved across previous and existing SARS-CoV-2 variants. VB10.2210 induced de novo T cell responses to all four non-Spike antigens.
VB10.16 in combination with atezolizumab demonstrated an ORR of 21%, including 2 CRs and 6 PRs, in a heavily pre-treated population of patients with HPV16-positive advanced cervical cancer.
VB10.16, a therapeutic vaccine and, an immunotherapy for the treatment of human papillomavirus 16 induced malignancies, is in Phase 2 for the treatment of cervical cancer.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
